[HTML][HTML] An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with …
JR Johnson, D Lossignol, M Burnell-Nugent… - Journal of pain and …, 2013 - Elsevier
Context Chronic pain in patients with advanced cancer poses a serious clinical challenge.
The Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (US Adopted
Name, nabiximols; Sativex®) is a novel cannabinoid formulation currently undergoing
investigation as an adjuvant therapy for this treatment group. Objectives This follow-up study
investigated the long-term safety and tolerability of THC/CBD spray and THC spray in
relieving pain in patients with advanced cancer. Methods In total, 43 patients with cancer …
The Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (US Adopted
Name, nabiximols; Sativex®) is a novel cannabinoid formulation currently undergoing
investigation as an adjuvant therapy for this treatment group. Objectives This follow-up study
investigated the long-term safety and tolerability of THC/CBD spray and THC spray in
relieving pain in patients with advanced cancer. Methods In total, 43 patients with cancer …
以上显示的是最相近的搜索结果。 查看全部搜索结果